Ignyta Inc., of San Diego, formed a clinical collaboration with the University of California, San Francisco (UCSF), which will study entrectinib in a multicenter, open-label, proof-of-concept trial in patients with metastatic melanoma that is positive for activating alterations in the tyrosine kinase receptors NTRK1/2/3 (encoding TrkA/TrkB/TrkC) or ROS1.